JP2019518713A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518713A5
JP2019518713A5 JP2018548878A JP2018548878A JP2019518713A5 JP 2019518713 A5 JP2019518713 A5 JP 2019518713A5 JP 2018548878 A JP2018548878 A JP 2018548878A JP 2018548878 A JP2018548878 A JP 2018548878A JP 2019518713 A5 JP2019518713 A5 JP 2019518713A5
Authority
JP
Japan
Prior art keywords
trail
polypeptide
polypeptide chain
amino acid
monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018548878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518713A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/022789 external-priority patent/WO2017161173A1/en
Publication of JP2019518713A publication Critical patent/JP2019518713A/ja
Publication of JP2019518713A5 publication Critical patent/JP2019518713A5/ja
Pending legal-status Critical Current

Links

JP2018548878A 2016-03-16 2017-03-16 癌療法のための改変ｔｒａｉｌ Pending JP2019518713A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662309352P 2016-03-16 2016-03-16
US62/309,352 2016-03-16
US201662323501P 2016-04-15 2016-04-15
US62/323,501 2016-04-15
US201762445556P 2017-01-12 2017-01-12
US62/445,556 2017-01-12
PCT/US2017/022789 WO2017161173A1 (en) 2016-03-16 2017-03-16 Engineered trail for cancer therapy

Publications (2)

Publication Number Publication Date
JP2019518713A JP2019518713A (ja) 2019-07-04
JP2019518713A5 true JP2019518713A5 (enExample) 2020-04-23

Family

ID=58413224

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548878A Pending JP2019518713A (ja) 2016-03-16 2017-03-16 癌療法のための改変ｔｒａｉｌ

Country Status (10)

Country Link
US (1) US20190077870A1 (enExample)
EP (1) EP3430034A1 (enExample)
JP (1) JP2019518713A (enExample)
KR (1) KR20180127407A (enExample)
CN (1) CN108884142A (enExample)
AU (1) AU2017234679A1 (enExample)
CA (1) CA3017622A1 (enExample)
IL (1) IL261267A (enExample)
MX (1) MX2018011219A (enExample)
WO (1) WO2017161173A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3348578B1 (en) * 2015-10-22 2019-10-09 Chengdu Huachuang Biotechnology Co., Ltd Double-target mutein mur6s4tr of trail, and preparation method and use thereof
JP2019517570A (ja) * 2016-06-13 2019-06-24 メリマック ファーマシューティカルズ インコーポレーティッド Ｔｒａｉｌベースの治療剤または細胞死受容体アゴニストを用いて患者を選択および治療する方法
CN109125709B (zh) * 2018-08-23 2021-10-22 成都华创生物技术有限公司 Trail突变体在制备治疗痤疮药物中的应用及一种制剂
WO2022080865A2 (ko) * 2020-10-13 2022-04-21 신동준 반려견의 항암용 재조합 단백질 및 이를 포함하는 반려견을 위한 항암용 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JPH0822239B2 (ja) * 1988-07-07 1996-03-06 株式会社蛋白工学研究所 変異ヒト腫傷壊死因子
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CN101633692A (zh) * 1999-06-28 2010-01-27 杰南技术公司 利用二价金属离子制备Apo-2配体的方法
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
SI1706424T1 (sl) 2004-01-12 2010-01-29 Applied Molecular Evolution Variante fc regij
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
ES2538122T3 (es) * 2008-07-21 2015-06-17 Apogenix Gmbh Moléculas de una sola cadena de TNFSF
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
EP2437767B1 (en) * 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
WO2011139681A1 (en) 2010-04-26 2011-11-10 Merrimack Pharmaceuticals Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
EP2468764A1 (en) * 2010-12-24 2012-06-27 Rijksuniversiteit te Groningen TNF family ligand variants
JP6047142B2 (ja) * 2011-04-01 2016-12-21 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
CN111592601A (zh) * 2011-07-06 2020-08-28 江苏靶标生物医药研究所有限公司 一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用
NO2776305T3 (enExample) * 2014-04-23 2018-01-27
US10428149B2 (en) * 2015-03-18 2019-10-01 Universitat Stuttgart Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof

Similar Documents

Publication Publication Date Title
US11919931B2 (en) Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)
JP2025063029A5 (enExample)
EP3998077B1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US8927693B2 (en) Fibronectin based scaffold domain proteins that bind IL-23
JP2023504914A5 (enExample)
JP2017527272A5 (enExample)
JP2017512063A5 (enExample)
JP2019512222A5 (enExample)
JP2019518713A5 (enExample)
JP2011501951A5 (enExample)
JP2014510518A5 (enExample)
PT2697257T (pt) Proteínas de fusão fc compreendendo novos ligantes ou arranjos
MX2012002428A (es) Compuestos de union il-17 y usos medicos de los mismos.
IL294059A (en) Mutant rsv f protein and its use
JP2015504052A5 (enExample)
JP2014510519A5 (enExample)
JP2020517260A5 (enExample)
JP2023503472A5 (enExample)
JP2024547218A5 (enExample)
JP2022530742A5 (enExample)
WO2013065343A1 (ja) 非ペプチドヒンジ部含有フレキシブル抗体様分子
WO2022109743A1 (en) Polypeptides targeting dr4 and/or dr5 and related compositions and methods
CN105669871A (zh) 一种胸腺肽α1的融合蛋白
US20220340629A1 (en) Myosin Derived Peptides and Related Compounds with Anticoagulant Activities
JP2025514872A5 (enExample)